OrbiMed’s Amedisys AMED Stock Holding History

OrbiMed’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-171,100	Closed	-$14.6M	–	153
2018 Q2	$14.6M	Sell	171,100 -36,400	-18%	-$2.67M	0.17%	103
2018 Q1	$12.5M	Hold	207,500	–	–	0.16%	98
2017 Q4	$10.9M	Buy	+207,500	New	+$10.9M	0.14%	102
2017 Q1	–	Sell	-71,500	Closed	-$3.05M	–	138
2016 Q4	$3.05M	Hold	71,500	–	–	0.04%	116
2016 Q3	$3.39M	Buy	71,500 +51,500	+258%	+$2.57M	0.04%	124
2016 Q2	$1.01M	Buy	+20,000	New	+$1.01M	0.01%	126

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

OrbiMed's AMED Position: Q3 2018 in Review

OrbiMed sold out of Amedisys (AMED) in Q3 2018, closing a stake of 171,100 shares — an estimated $14.6M sold.

OrbiMed first reported a position in AMED in Q2 2016 and held it in 6 quarters. The position peaked at $14.6M in Q2 2018. 265 funds tracked by Wall St. Rank hold AMED as of Q3 2018.

OrbiMed reported no remaining Amedisys position as of Q3 2018 after selling out during the quarter.
OrbiMed sold 171,100 Amedisys shares in Q3 2018, an estimated $14.6M.
OrbiMed first reported a position in Amedisys in Q2 2016 and held it in 6 quarters.
OrbiMed's Amedisys position peaked at $14.6M in Q2 2018.
265 funds tracked by Wall St. Rank held Amedisys as of Q3 2018.

Based on OrbiMed's 13F filing for Q3 2018, filed 14 Nov 2018.